Anifrolumab

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Healthy Participants Study

Conditions

Healthy Participants Study

Trial Timeline

Mar 22, 2022 → Apr 13, 2023

NCT ID

NCT05339100

About Anifrolumab

Anifrolumab is a phase 1 stage product being developed by AstraZeneca for Healthy Participants Study. The current trial status is completed. This product is registered under clinical trial identifier NCT05339100. Target conditions include Healthy Participants Study.

What happened to similar drugs?

20 of 20 similar drugs in Healthy Participants Study were approved

Approved (20) Terminated (1) Active (0)

✅mRNA-1273.712ModernaApproved

✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved

✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved

✅Olmesartan medoxomil + Irbesartan + ValsartanDaiichi SankyoApproved

✅Perampanel 6 MGEisaiApproved

✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved

✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04750057	Pre-clinical	Completed	—	—	Systemic Lupus Erythematosus
NCT07431775	Pre-clinical	Recruiting	Oct 1, 2026	Mar 31, 2032	Systemic Lupus Erythematosus
NCT07430306	Phase 3	Recruiting	Apr 1, 2026	Jan 26, 2029	Systemic Lupus Erythematosus
NCT07000110	Pre-clinical	Recruiting	Jan 26, 2026	Nov 30, 2031	Systemic Lupus Erythematosus
NCT06594068	Approved	Recruiting	Jan 16, 2026	Aug 31, 2027	Systemic Lupus Erythematosus
NCT07330245	Pre-clinical	Recruiting	Dec 31, 2025	Sep 30, 2028	Lupus Erythematosus, Systemic
NCT06795893	Pre-clinical	Recruiting	Nov 7, 2025	Apr 15, 2031	Systemic Lupus Erythematosus
NCT06659029	Pre-clinical	Recruiting	Jul 1, 2025	Apr 15, 2031	Systemic Lupus Erythematosus
NCT06673043	Pre-clinical	Recruiting	Feb 28, 2025	Jun 30, 2028	Lupus Erythematosus, Systemic
NCT06662123	Phase 1	Completed	Oct 21, 2024	Jan 10, 2025	Healthy Volunteers
NCT06374212	Phase 2	Active	Jun 21, 2024	Apr 1, 2026	Hidradenitis Suppurativa
NCT05339100	Phase 1	Completed	Mar 22, 2022	Apr 13, 2023	Healthy Participants Study
NCT05001698	Phase 1	Completed	Jul 27, 2021	Jun 2, 2022	Systemic Lupus Erythematosus

Competing Products

20 competing products in Healthy Participants Study

See all competitors

Product	Company	Stage	Hype Score
Use of Wearable Digital Sensors After mRNA Vaccination in Adults	Moderna	Preclinical	0
mRNA-0184	Moderna	Phase 1	0
mRNA-6231	Moderna	Phase 1	0
Letrozole	Dr. Reddy's Laboratories	Phase 1	26
Isotretinoin	Dr. Reddy's Laboratories	Phase 1	26
Fexofenadine	Dr. Reddy's Laboratories	Phase 1	26
Sertraline	Dr. Reddy's Laboratories	Phase 1	26
Nizatidine + Axid	Dr. Reddy's Laboratories	Phase 1	26
Anastrozole	Dr. Reddy's Laboratories	Phase 1	26
mRNA-1273.712	Moderna	Approved	0
Risperidone	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
Metformin + Glucophage	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
mRNA-0184	Moderna	Phase 1	0
Divalproex Sodium	Dr. Reddy's Laboratories	Phase 1	26
Sirolimus	Dr. Reddy's Laboratories	Phase 1	26
Glimepiride	Dr. Reddy's Laboratories	Phase 1	26
Ziprasidone Hydrochloride	Dr. Reddy's Laboratories	Phase 1	26
Naproxen sodium	Dr. Reddy's Laboratories	Phase 1	26